Joel F. Martin

Argonaut Technologies, Inc. develops, manufactures, and markets products that enable chemists to use high speed parallel synthesis in the development of new drugs

Hypnion, Inc. discovered and developed neuroscience drugs. It focused on the development of novel therapeutics for the treatment of central nervous system disorders to serve the underserved markets of sleep and wake-alertness disorders and circadian rhythm abnormalities. The company was founded in 2000 and was headquartered in Lexington, MA.

Quantum Dot Corp. develops and markets novel solutions for biomolecular detection. Its products and services employ quantum dot particles, tiny semiconductor crystals that emit light brightly in a range of sharp colors. The company was founded by Bala Manian in 1998 and is located in Hayward, CA.

Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA.

Institutional Venture Partners (Institutional Venture Partners) is a venture capital firm founded in 1980 by Reid Dennis. The firm is headquartered in Menlo Park, California.

Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California.

Forward Ventures Services LLC (Forward Ventures ) is a venture capital firm founded in 1990 by Standish M. Fleming and Ivor Royston. The firm is headquartered in San Diego, California.

Altair is a privately owned company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to both near term clinical stage opportunities, as well as early stage development projects. Altair's first compound AIR645 is currently in phase I clinical trials. This first in class compound posses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and COPD. Additionally, the characteristics of the 2'-MOE Gapmer chemistry provides for the possibility of administration of AIR645 as an inhaled therapeutic delivered once weekly. Altair is also planning on developing a future pipeline of other best-in-class molecules for respiratory targets by exploiting the advantages of its propriety 2nd generation antisense oligonucleotide chemistry.

Dauntless 1, Inc. engages in pharmaceuticals. The company is headquartered in San Diego, CA.